These strategies can now be validated and optimised in prospective clinical studies, and can be extended to identify other important molecular alterations, such as ATRX loss, 1p/19q co-deletion and/or MGMT hypermethylation, with which brain cancer type can be stratified pre-operatively. The gene discussed is ATRX; the disease is brain cancer.